Clinical trial
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With…
NCT00088179 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00088179 |
|---|---|
| Title | Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | pexelizumab in conjunction with CABG |
| Enrollment | 4,000 |
| Start date | Jul 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jul 23, 2004 |
| Last update posted | Feb 22, 2018 |
| Countries | France, Germany, Netherlands, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: